|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2003-7-14
|
|
pubmed:abstractText |
Hyperhomocysteinemia adversely affects the endothelium, although the exact mechanism is unclear. Systemic lupus erythematosus (SLE) is an inflammatory disease with a high atherothrombotic tendency. We examined whether acute hyperhomocysteinemia exacerbates endothelial and platelet dysfunction in patients with SLE.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
30
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1479-84
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12858444-Acute Disease,
pubmed-meshheading:12858444-Administration, Oral,
pubmed-meshheading:12858444-Adult,
pubmed-meshheading:12858444-Brachial Artery,
pubmed-meshheading:12858444-Endothelium, Vascular,
pubmed-meshheading:12858444-Female,
pubmed-meshheading:12858444-Flow Cytometry,
pubmed-meshheading:12858444-Humans,
pubmed-meshheading:12858444-Hyperhomocysteinemia,
pubmed-meshheading:12858444-Lupus Erythematosus, Systemic,
pubmed-meshheading:12858444-Male,
pubmed-meshheading:12858444-Methionine,
pubmed-meshheading:12858444-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:12858444-Platelet Activation,
pubmed-meshheading:12858444-Regional Blood Flow,
pubmed-meshheading:12858444-Vasodilation,
pubmed-meshheading:12858444-von Willebrand Factor
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Patients with systemic lupus erythematosus show increased platelet activation and endothelial dysfunction induced by acute hyperhomocysteinemia.
|
|
pubmed:affiliation |
Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin. tamls_813@yahoo.com
|
|
pubmed:publicationType |
Journal Article
|
